Supravalvular Aortic Stenosis: Causes, Symptoms, & Treatment

Supravalvular aortic stenosis (SVAS) is a congenital narrowing of the aorta that occurs just above the aortic valve, restricting blood flow out of the heart. It affects roughly 1 in 20,000 newborns and is caused by mutations in the gene responsible for producing elastin, the protein that gives arteries their stretch and resilience.¹ While many people associate it with Williams syndrome, SVAS also occurs on its own or runs in families without the broader syndrome, and the distinction matters for how the condition behaves over a lifetime.

Why the Aorta Narrows

The root cause of SVAS is a shortage of functional elastin. The elastin gene, called ELN, sits on chromosome 7. When one copy of that gene is deleted or carries a disabling mutation, the body produces only about half the elastin it needs. That shortfall is enough to cause problems in the aortic wall.² Smooth muscle cells in the vessel wall, deprived of their normal elastic framework, multiply excessively and pile up extra collagen. The result is a thickened, stiff arterial wall with broken and disorganized elastic fibers, and the once-flexible aorta becomes a rigid tube with a narrowed opening.³

The genetic picture is not always simple. Some mutations knock out the entire gene copy through a large chromosomal deletion, while others are smaller point mutations that scramble the gene’s instructions. Research on patient cells has shown that many of these mutant gene copies produce faulty messenger RNA that the cell’s quality-control system simply destroys, confirming that the problem is having too little elastin rather than producing a toxic version of it.⁴ In rare cases, though, a mutation can produce a shortened, abnormal elastin protein that actively interferes with normal fiber assembly, creating a more aggressive form of disease.⁴

SVAS follows an autosomal dominant inheritance pattern with variable expressivity. That means a parent who carries the mutation has a 50-50 chance of passing it to each child, but two people with the same mutation can end up with very different degrees of narrowing. Some family members may have severe obstruction requiring surgery in childhood, while a relative with the identical genetic change might go decades with only a mild murmur.

Williams Syndrome and Non-Syndromic Forms

About half of SVAS cases occur in the context of Williams syndrome (also called Williams-Beuren syndrome), a condition caused by a deletion of roughly 26 to 28 genes on chromosome 7, including the elastin gene. People with Williams syndrome have a recognizable cluster of features: an outgoing personality, developmental delays, distinctive facial features, and elevated blood calcium in infancy, along with their cardiovascular problems. The remaining cases are either familial (passed through generations with an isolated elastin gene mutation) or sporadic (appearing for the first time in a family).¹

The cardiovascular profile differs between the two groups in important ways. Patients with Williams syndrome are more likely to develop branch pulmonary artery stenosis, renal artery stenosis, and high blood pressure than those with non-Williams SVAS.⁵ Interestingly, the Williams syndrome group also tends to start with lower peak velocities across the narrowing, suggesting their aortic obstruction may be milder at baseline. Yet when researchers look at long-term event-free survival, the presence or absence of Williams syndrome does not appear to change the overall outlook significantly.⁶ The takeaway for families is that whether SVAS comes with Williams syndrome or not, close cardiovascular follow-up is equally important.

Symptoms and How the Condition Is Found

Many children with SVAS are first identified not because of symptoms but because a doctor hears a heart murmur during a routine exam. A characteristic harsh systolic murmur, heard best at the base of the heart, often prompts further investigation. In milder cases, a child can remain asymptomatic for years. One early case report described a boy whose murmur was detected at two months of age but who felt perfectly fine until age eight, when he began to notice mild shortness of breath with exercise and occasional chest discomfort.⁷

When symptoms do appear, they tend to reflect the heart working harder than it should against a narrowed outflow tract. Common complaints include:

• Exercise intolerance: getting winded or fatigued sooner than peers during physical activity.
• Chest pain: typically with exertion, caused by the heart muscle not receiving enough oxygen to meet its increased workload.
• Dizziness or fainting: a worrying sign that blood flow to the brain may be compromised during activity.

One unusual physical finding can be a clue at the bedside. Because the aortic narrowing sits just above the valve, the high-velocity jet of blood tends to be directed preferentially into the brachiocephalic artery, which feeds the right arm. This can make the blood pressure in the right arm noticeably higher than in the left. In one documented case, the difference was 25 mmHg, a phenomenon driven by the Coanda effect, in which a fluid jet clings to a nearby wall and gets steered in one direction.⁸ Checking blood pressure in both arms is a simple test that can raise suspicion for this condition.

The Trouble Beyond the Aorta

SVAS is sometimes described as a “simple lesion,” but that label is misleading. Because elastin is a building material used throughout the arterial system, the disease process rarely confines itself to one spot. A CT angiography study of 26 patients found that the narrowing existed in two morphological patterns: a discrete, hourglass-shaped constriction in about half of patients and a more diffuse, tunnel-like narrowing of the ascending aorta in the other half.⁹ In severe cases the aorta can narrow dramatically; one adult patient’s supravalvular segment had shrunk to roughly the diameter of a coronary artery, far smaller than it should be.¹⁰

Pulmonary artery involvement is common. Obstructions somewhere in the pulmonary vascular tree have been described in up to 83% of patients with elastin arteriopathy, whether or not they have Williams syndrome.¹¹ The good news is that peripheral pulmonary artery stenosis often improves on its own during childhood as the vessels grow, so it does not always require treatment.¹¹

The coronary arteries sit in a particularly vulnerable position. They branch off the aorta just below the stenosis, where they are exposed to abnormally high pressure. Over time, this chronic pressure can promote the growth of the same dysplastic tissue that narrows the aorta, gradually obstructing the coronary arteries themselves.¹² In the same CT angiography study mentioned earlier, roughly 58% of patients had some form of coronary artery involvement, including narrowing, blockage, or dilation.⁹ This is one reason SVAS carries more risk than other forms of aortic stenosis: even when the aortic narrowing looks moderate, the coronary arteries may be silently compromised.

Diagnosis and Imaging

Echocardiography is typically the first tool used to confirm SVAS. It can visualize the narrowing above the aortic valve, measure the speed of blood flow across it (which indicates how severe the obstruction is), and check for associated problems like thickened valve leaflets or left ventricular hypertrophy. A peak velocity measured by echo gives clinicians a noninvasive way to grade severity and track changes over time.

When more anatomic detail is needed, especially before surgery, CT angiography or cardiac MRI fills in the picture. CT is particularly useful for mapping the exact extent of the narrowing, identifying whether the coronary arteries are involved, and spotting stenosis in the pulmonary arteries or aortic arch branches. In a pediatric imaging series, CT revealed aortic valve abnormalities such as leaflet thickening or partial fusion of cusps to the sinotubular junction in about 58% of patients, findings that directly affect how surgeons plan their repair.⁹ Cardiac catheterization, once the gold standard, is now reserved mainly for cases where noninvasive imaging is inconclusive or when a catheter-based intervention is being considered.

Genetic testing plays a supporting role. When SVAS is found, testing for elastin gene mutations or the broader Williams syndrome deletion can clarify the underlying cause. This matters not only for the patient’s own management but also for family planning, since parents carrying an ELN mutation have a significant chance of passing it on.

Surgical Repair

Surgery is the primary treatment for SVAS that causes significant obstruction. Intervention is generally recommended when the pressure gradient across the narrowing is high enough to burden the heart or when symptoms appear. Several surgical techniques have been developed over the decades, and they differ in how effectively they restore normal aortic geometry.

The simplest approach, the single-patch (or McGoon) repair, involves cutting into the narrowed segment through one aortic sinus and sewing in a patch to widen it. This works but tends to leave an asymmetric repair. The Doty operation extends the incision into a different sinus (the noncoronary sinus) and uses a more anatomic patch placement. The most symmetric reconstruction is the Brom three-patch technique, which widens all three sinuses of Valsalva individually. In a comparative study, patients who received the Brom repair had a mean residual gradient of about 11 mmHg, compared with 30 mmHg after a Doty repair and 45 mmHg after a single-patch approach. Only about 9% of Brom patients had significant residual obstruction, and the rate of meaningful aortic valve leakage was under 5%.¹³

For patients with diffuse narrowing that extends well beyond the sinotubular junction, a more extensive operation may be required, sometimes involving replacement of the ascending aorta with a graft. In one reported adult case, the narrowing was so severe that the surgeon replaced the ascending aorta entirely and used a pantaloon-shaped graft to reconstruct the supravalvular area, bringing the pressure gradient down from 48 to 8 mmHg.¹⁰

Balloon angioplasty, a catheter-based technique, is not a standard treatment for congenital SVAS but has been used successfully in specific situations, such as when supravalvular narrowing develops as a complication after another cardiac surgery. In those select cases, inflating a balloon across the stenosis improved both the pressure gradient and the angiographic appearance of the vessel.¹⁴

The Anesthesia Risk That Gets Overlooked

One of the most important and underappreciated dangers of SVAS is the risk of sudden cardiac events during sedation or general anesthesia. The anatomy creates a perfect storm for the heart muscle to run short of oxygen. The narrowed aorta forces the left ventricle to thicken (hypertrophy), which increases its oxygen demand. At the same time, the coronary arteries, which sit upstream of the obstruction in a high-pressure zone, may be narrowed themselves, limiting oxygen delivery.¹⁵

Anesthesia compounds the problem by lowering blood pressure and heart rate, reducing the already compromised coronary perfusion even further. In some patients, the free edge of an aortic valve cusp can fuse with the prominent ridge at the sinotubular junction, physically blocking a coronary ostium. This combination of supply-and-demand mismatch can trigger fatal heart rhythms even in patients whose aortic obstruction appears only moderate on imaging.¹⁶ Anyone with known or suspected SVAS should ensure that any anesthesiologist involved in their care is aware of the condition before any procedure, no matter how minor it seems.

Long-Term Outlook After Surgery

Surgical repair of SVAS carries real but manageable risks. A large systematic review and meta-analysis pooling data across many centers found that early surgical mortality was about 4%, and late mortality after hospital discharge ran at roughly 0.6% per patient-year. Using microsimulation modeling, the researchers estimated that a child who undergoes SVAS repair at an average age of about five could expect a life span reaching roughly 91% of what an age-matched person in the general population would live.¹⁷

Reoperation is a significant consideration. The same analysis estimated that over a 30-year horizon after initial repair, about 31% of patients would need some form of reintervention, with the majority of those being for problems at the original repair site.¹⁷ A single-center study echoed these figures, reporting survival rates of about 94% at five, ten, and twenty years but freedom from left ventricular outflow tract reoperation dropping from roughly 79% at five years to 70% at twenty years. The risk of needing reoperation was higher for children operated on before age one and for those who required additional right ventricular outflow tract repair at the same time.¹⁸

For adults living with repaired or unrepaired SVAS, the data are encouraging but underscore the need for lifelong monitoring. A study that followed 65 adults with SVAS for a median of 13 years found 10-year survival of 95% and event-free survival of 83%. Arrhythmias were the most common cardiovascular events during follow-up. Having Williams syndrome, being male or female, or having had previous surgery did not significantly alter the likelihood of remaining event-free.⁶

Emerging Research Into the Disease Mechanism

Understanding exactly how reduced elastin leads to the overgrowth of smooth muscle cells in the aortic wall has been a longstanding challenge. Recent laboratory work has taken a novel approach: creating smooth muscle cells from induced pluripotent stem cells derived from SVAS patients and studying them in culture. These patient-derived cells replicate the hallmarks of the disease, proliferating faster than normal smooth muscle cells and failing to organize their internal structural fibers properly. Researchers found that adding recombinant elastin protein to the culture, or boosting a particular signaling pathway called RhoA, could rescue the abnormal fiber organization. They also identified overactive signaling through a pathway called ERK1/2 as a driver of the excessive cell proliferation.¹⁹

These findings are still in the laboratory phase, far from any treatment you could receive in a clinic. But they represent a shift in how researchers think about SVAS. If the smooth muscle overgrowth can be tamed pharmacologically, it might one day be possible to slow the progression of arterial narrowing in patients who carry the genetic mutation, buying time before surgery becomes necessary or reducing the chance that a repaired segment re-narrows. For now, surgical correction and vigilant long-term surveillance remain the cornerstones of management.